Brief: Hillstream Biopharma Signs An Exclusive Option Agreement To Advance Next-Generation Anti-Muc1-C Agents For Drug Resistant Cancers
31/01/2023 13:29
Jan 31 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM BIOPHARMA SIGNS AN EXCLUSIVE OPTION AGREEMENT
TO
ADVANCE NEXT-GENERATION ANTI-MUC1-C AGENTS FOR DRUG RESISTANT
CANCERS
* HILLSTREAM BIOPHARMA INC - DEVELOPMENT EXPECTED TO
CAPITALIZE
UPON TUMOR TARGETING QUATRAMERS
* HILLSTREAM BIOPHARMA INC - SIGNED EXCLUSIVE OPTION
AGREEMENT
WITH DANA-FARBER CANCER INSTITUTE TO LICENSE TECHNOLOGY
TARGETING MUC1-C ONCOPROTEIN
Source text for Eikon: ID:nGNX94ghRf
Further company coverage: HILS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing